WAYNE, Pa. — Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will present two posters featuring previously reported results from its Phase 3 SELVA and Phase 2 TOIVA clinical studies of QTORIN™ rapamycin, along with additional new pediatric analyses, at the Pediatric Dermatology Research Alliance (PeDRA) Annual Conference, taking place October 15–17, 2026, in Alexandria, Virginia. Copies of the posters are available here in the “Publications & Presentations” section of Palvella’s website.
“Microcystic lymphatic malformations and cutaneous venous malformations are serious, rare genetic diseases that can cause bleeding and chronically debilitating complications beginning in childhood and continuing throughout life,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics. “These encouraging pediatric findings highlight the potential of QTORIN™ rapamycin to address disease manifestations early in life, before these conditions progress and cause further complications. We continue to advance QTORIN™ rapamycin with a sense of urgency for both of these serious, rare diseases, with the objective of delivering a first-in-disease FDA-approved therapy that meaningfully improves the lives of affected children and adults.”
Details of the Poster Presentations
Title: Phase 3 SELVA: Investigational QTORIN™ Sirolimus Topical Gel 3.9% Improved Disease Severity and Key Lesion Characteristics in Children With Microcystic Lymphatic Malformations
Poster Number: 036
Session: Poster reception
Date/Time: October 15, 2026, 5:00–7:00 p.m.
Location: Poster Hall
Presenter: Kristen Kahle, Ph.D.
Title: Phase 2 TOIVA: Overall Disease Severity and Lesion Bleeding Were Reduced in Pediatric Participants With Cutaneous Venous Malformations Treated With Investigational QTORIN™ Sirolimus Topical Gel 3.9%
Poster Number: 035
Session: Poster reception
Date/Time: October 15, 2026, 5:00–7:00 p.m.
Location: Poster Hall
Presenter: Kristen Kahle, Ph.D.
In addition to the scientific presentations, Palvella will feature its BEYOND mLM disease awareness initiative at the PeDRA Annual Conference through a dedicated booth focused on education and awareness of microcystic lymphatic malformations. BEYOND mLM and its educational website, BEYONDmLM.com, were developed in collaboration with PeDRA, the Consortium of iNvestigators of Vascular AnomalieS (CaNVAS), The Lymphatic Malformations Alliance (formerly known as Lymphangiomatosis & Gorham’s Disease Alliance), the Lymphatic Education & Research Network (LE&RN), and VAccess.org.
About Palvella Therapeutics
Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients living with serious, rare skin diseases and vascular anomalies for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular anomalies, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).
QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.
Contact Information
Investors
Wesley H. Kaupinen
Founder and CEO
Palvella Therapeutics
[email protected]
Media
Marcy Nanus
Vice President, Investor Relations and Corporate Affairs
Palvella Therapeutics
[email protected]